GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
36.47
-1.81 (-4.73%)
NYSE · Last Trade: Jul 17th, 5:40 PM EDT
Detailed Quote
Previous Close
38.28
Open
37.95
Bid
36.44
Ask
36.50
Day's Range
35.45 - 38.25
52 Week Range
31.72 - 44.67
Volume
14,696,740
Market Cap
196.40B
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
1.716 (4.71%)
1 Month Average Volume
5,439,155
Chart
About GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK)
GSK Plc is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. The company specializes in the research, development, and manufacturing of a wide range of pharmaceuticals, vaccines, and consumer health products. GSK's portfolio covers various therapeutic areas, including respiratory diseases, HIV, oncology, immunology, and infectious diseases, with a strong emphasis on innovation and scientific advancement. Committed to addressing health challenges, GSK collaborates with various partners and stakeholders to deliver accessible healthcare solutions that meet the needs of patients and communities around the world. Read More
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster). The new prefilled syringe removes the need to reconstitute separate vials prior to administration, simplifying the vaccine administration process for healthcare professionals.
Fluarix and Flulaval are being shipped in single-dose, 0.5 mL pre-filled syringes and are not recommended for individuals with severe allergies to vaccine components or a history of Guillain-Barré syndrome.
GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older.
The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates.
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election.
Senator Maggie Hassan is investigating GSK's discontinuation of Flovent HFA, citing increased hospitalizations, higher drug costs, and lost Medicaid rebates.
GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a 200 mg/mL autoinjector of Benlysta (belimumab), a B-lymphocyte stimulator (BlyS)-specific inhibiting monoclonal antibody, for subcutaneous injection in patients five years of age and older with active lupus nephritis (LN) who are receiving standard therapy. With this approval, GSK is expanding choices for belimumab treatment, offering pediatric lupus nephritis patients and caregivers a first-of-its-kind subcutaneous option that can be administered at home. The 200 mg/mL autoinjector was approved for pediatric patients with active systemic lupus erythematosus (SLE) in 2024.
GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support individuals impacted with lupus, particularly systemic lupus erythematosus (SLE) and lupus nephritis (LN).
Kennedy said the Department of Health and Human Services would retire all 17 current members of the ACIP, citing what he called a "crisis of public trust."
